Title :

Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study.

Author(s) :

Panhaleux, M. [Auteur]
Espitia, O. [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Terrier, B. [Auteur]
Service de médecine interne et centre de référence des maladies rares [CHU Cochin]
Manson, G. [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
Maria, A. [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Humbert, S. [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Godbert, B. [Auteur]
Perrin, J. [Auteur]
Achille, A. [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Arrondeau, J. [Auteur]
Kostine, M. [Auteur]
CHU Bordeaux
Fallet, V. [Auteur]
Sorbonne Université [SU]
Pugnet, G. [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Chaigne, B. [Auteur]
Service de médecine interne et centre de référence des maladies rares [CHU Cochin]
Champiat, S. [Auteur]
Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] [DITEP]
Laparra, A. [Auteur]
Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] [DITEP]
Danlos, F. X. [Auteur]
Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] [DITEP]
Launay, David [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Lambotte, O. [Auteur]
Service de Médecine Interne - Immunologie Clinique [AP-HP Bicêtre]
Michot, J. M. [Auteur]
Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] [DITEP]
Forestier, A. [Auteur]

Journal title :

European Journal of Cancer

Abbreviated title :

Eur J Cancer

Volume number :

160

Pages :

p. 134-139

Publication date :

2022-01

ISSN :

1879-0852

English keyword(s) :

Anti-PD-L1 immunotherapy
Anti-PD1 immunotherapy
Systemic sclerosis
Immune checkpoint inhibitor

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Objectives Cancer patients with pre-existing autoimmune disease, such as systemic sclerosis (SSc), are excluded from clinical trials, so the data on tolerability and efficacy of immune checkpoint inhibitors in these ...
Show more >Objectives Cancer patients with pre-existing autoimmune disease, such as systemic sclerosis (SSc), are excluded from clinical trials, so the data on tolerability and efficacy of immune checkpoint inhibitors in these patients are limited. This study investigated the tolerability and efficacy of anti–programmed death ligand 1 (PD (L)1) immunotherapies in patients with pre-existing SSc. Methods Scleronco-01 was a multicentre, nationwide, open-label, phase IV observational study, from 2019 to 2021. Results Seventeen SSc patients receiving treatment for lung carcinoma (n = 13, 77%), head and neck cancer (n = 2, 12%), melanoma (n = 1, 6%), and colorectal carcinoma (n = 1, 6%) were included. The median (interquartile range) patient age was 60 (34–82) years. Fifteen (88%) patients received anti-PD1 (nivolumab and pembrolizumab) and two (12%) anti-PD-L1 (durvalumab). The median follow-up duration was 12 (range, 2–38) months. Four patients (24%) experienced flare-up of SSc symptoms. Ten patients (59%) developed an immune-related adverse event (grade I–II in 11 patients [65%], grade III–IV in one [6%]) without grade V. The overall response rate was 41% (7/17 patients). The median overall survival was 15.8 (95% confidence interval: 7.3 to not reached) months. Conclusion Anti-PD1 or PD-L1 immunotherapies are suitable options for cancer patients with pre-existing SSc. Longer follow-up periods are required for long-term safety analyses.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2023-11-15T05:30:35Z
2024-02-27T11:01:15Z
2024-02-27T14:26:32Z